Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  IDEXX Laboratories    IDXX

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

IDEXX Laboratories : Today's Research Report Coverage on Healthcare Stocks -- AMAG Pharma, IDEXX Laboratories, Palatin Technologies, and Bio-Path

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20/2017 | 12:21pm CEST

NEW YORK, September 20, 2017 /PRNewswire/ --

If you want a Stock Review on AMAG, IDXX, PTN, or BPTH then come over to http://dailystocktracker.com/register and sign up for your free customized report. Today's attention is directed to the Healthcare sector, which is the category of stocks relating to medical and healthcare goods or services. The sector includes hospital management firms, health maintenance organizations, biotechnology, and a variety of medical products. This morning, DailyStockTracker.com scans the recent performance of AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE MKT: PTN), and Bio-Path Holdings Inc. (NASDAQ: BPTH). Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at:


AMAG Pharmaceuticals 

On Tuesday, shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. recorded a trading volume of 1.19 million shares, which was above their three months average volume of 837,940 shares. The stock ended the session 1.04% lower at $19.05. The Company's shares have gained 11.08% in the last one month and 13.06% over the previous three months. The stock is trading 2.30% above its 50-day moving average. Moreover, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have a Relative Strength Index (RSI) of 53.45.

On September 07th, 2017, AMAG Pharma announced the appointment of Laura Williams, M.D., M.P.H. as Senior Vice President of clinical development, effective immediately. She will report to Julie Krop, M.D., Chief Medical Officer and Senior Vice President of clinical development and regulatory affairs at the Company.

On September 08th, 2017, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock, with a target price of $26 per share. The free research report on AMAG is available at:


IDEXX Laboratories 

Westbrook, Maine headquartered IDEXX Laboratories Inc.'s stock closed the day 0.97% lower at $160.53 with a total trading volume of 440,456 shares. The Company's shares have advanced 6.71% in the past month and 36.89% since the start of this year. The stock is trading 1.44% and 7.69% above its 50-day and 200-day moving averages, respectively. Additionally, shares of IDEXX Labs, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, have an RSI of 56.51.

On August 23rd, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'. The complimentary report on IDXX can be downloaded at:


Palatin Technologies 

Shares in Cranbury, New Jersey-based Palatin Technologies Inc. recorded a trading volume of 1.29 million shares. The stock ended yesterday's trading session 0.56% lower at $0.63. The Company's shares have surged 52.21% in the past month, 69.37% in the previous three months, and 24.03% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 39.03% and 48.47%, respectively. Furthermore, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have an RSI of 72.67.

On September 12th, 2017, Palatin Technologies announced that Anthony M. Manning, Ph.D. was appointed to its Board of Directors on September 07th, 2017. Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc.,  Cambridge, Massachusetts. Visit us today and download our complete research report on PTN for free at:


Bio-Path Holdings 

Bellaire, Texas-based Bio-Path Holdings Inc.'s stock finished Tuesday's session 9.21% lower at $0.34 with a total trading volume of 324,397 shares. The Company's shares have advanced 19.96% in the last one month. The stock is trading above its 50-day moving average by 3.27%. Additionally, shares of Bio-Path, which operates as a clinical and preclinical stage oncology focused antisense drug development company in the US, have an RSI of 54.68.  Get free access to your technical report on BPTH at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Email: [email protected] 
        Phone number:  (207) 331.3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20 IDEXX LABORATORIES : Today's Research Report Coverage on Healthcare Stocks -- AM..
09/08 IDEXX LABORATORIES : to Present at Bank of America Merrill Lynch Global Healthca..
09/07 DELTA AIR LINES : Three Companies Receive Honorable Mention from the C. Everett ..
09/06 IDEXX LABORATORIES : to Present at Bank of America Merrill Lynch Global Healthca..
09/02 IDEXX LABORATORIES : U.S. Patents Awarded to Inventors in Maine (Sept. 2)
09/02 IDEXX LABORATORIES : U.S. Patents Awarded to Inventors in Missouri (Sept. 2)
08/17 IDEXX LABORATORIES : Studies from IDEXX Laboratories Inc. Yield New Information ..
08/17 IDEXX LABORATORIES : New Immunoglobulins Study Findings Have Been Reported by Re..
08/10 IDEXX LABORATORIES : Researchers Submit Patent Application, "Method and Device f..
08/08 IDEXX LABORATORIES : to Host 2017 Investor Day
More news
News from SeekingAlpha
09/14 IDEXX Laboratories (IDXX) Presents At Bank Of America Merrill Lynch 2017 Glob..
09/14 Arconic Could Be For Sale - Cramer's Lightning Round (9/13/17)
08/23 Premarket analyst action - healthcare
08/23 12 Factors Behind The Rally - Cramer's Mad Money (8/22/17)
08/18 DAILY INSIDER RATINGS ROUND UP 8/16/ : Akam, wair, frgi, aat, lnce, crzo, pwon
Financials ($)
Sales 2017 1 954 M
EBIT 2017 412 M
Net income 2017 285 M
Debt 2017 648 M
Yield 2017 -
P/E ratio 2017 49,60
P/E ratio 2018 44,48
EV / Sales 2017 7,37x
EV / Sales 2018 6,67x
Capitalization 13 746 M
Duration : Period :
IDEXX Laboratories Technical Analysis Chart | IDXX | US45168D1046 | 4-Traders
Technical analysis trends IDEXX LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 154 $
Spread / Average Target -2,2%
EPS Revisions
Jonathan W. Ayers Chairman, President & Chief Executive Officer
Brian P. McKeon Chief Financial Officer, Treasurer & Executive VP
Ken Grady Chief Information Officer & Vice President
Rebecca M. Henderson Independent Director
Bill T. End Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC12.54%107 961